\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesInsufficient climate finance is a pressing challenge for local and regional authorities eager to undertake climate adaptation actions.
The Mission Implementation Platform (MIP4Adapt) has published the Funding and Financing Guide to provide a path to financial resources and enhancing preparedness before seeking funding or financing.
The guide introduces diverse funding and financing options, such as grants, PPPs, crowdfunding, and philanthropic funds, each explained with benefits for informed decision-making.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
AI Continent Deployment: Best use of technologies
The LDT4SSC (Local Digital Twins for Smart and Sustainable Communities) project has opened a new cascade funding call to local network of cities, regions, and digital innovators. This call supports co-funding for three Work Strands with a minimum available budget of 10.8 Million euros: - Work strand 1 - interconnecting existing LDTs: At least... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
